NUTREAT: Nutrition Throughout the Treatment Course - Expanding Care From Hospital to Home

Sponsor
University of Oslo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05997329
Collaborator
Oslo University Hospital (Other), University of South-Eastern Norway (Other)
125
2
2
28
62.5
2.2

Study Details

Study Description

Brief Summary

Patients with cancer have increased risk of malnutrition due to the disease itself and the treatment regimen they undergo. This is particularly relevant for patients with head and neck cancer (HNC), where 74%-95% are malnourished. HNC is a heterogenous group of cancers, including oral cavity, larynx, pharynx and salivary glands. The present project will study the effectiveness and implementation of remote patient monitoring of nutrition and tailored nutrition support throughout the treatment course in patients with head and neck cancer. The implementation will be evaluated in a randomized controlled trial (RCT), and the aim of the project is to reduce the prevalence of malnutrition and increase the quality of life among patients with HNC.

Condition or Disease Intervention/Treatment Phase
  • Other: App for diet record (MyFood)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
125 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Nutrition Throughout the Treatment Course - Expanding Care From Hospital to Home
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: MyFood (App for diet record)

Use of an App for diet record

Other: App for diet record (MyFood)
Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.

No Intervention: Usual care

Usual care

Outcome Measures

Primary Outcome Measures

  1. Malnutrition [17 weeks]

    Patient-Generated Subjective Global Assessment (PG-SGA). The tool categories participants into: category A (Well-nourished), B (Moderately malnutrition or possible malnutrition), or C (serious malnutrition)

Secondary Outcome Measures

  1. Weight change [During the 17 weeks]

    weight measurements

  2. Nutrition intake [Monthly up to three months]

    24-hour recall interviews

  3. Body composition [Monthly up to three months]

    Bioelectrical Impedance Analysis (BIA)

  4. Health-related quality of life [Monthly up to three months]

    EuroQol Research Foundation, Netherlands (EQ5D-5L). Assess health in 5 dimensions each of which has three response levels (1: No problems, 2: some problems and 3: extreme problems/unable to do).

  5. Number of Participants compliant to the intervention [At 17 weeks]

    Review of reported use of the MyFood app in the electronic patient record

  6. Number of patients with non-elective readmissions [At 17 weeks]

    Review of readmissions in the electronic patient record

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Head and neck cancer

  • Older than 18 years

Exclusion Criteria:
  • Patients admitted with the classification of malignant tumors (TNM) stage 4

  • Terminal condition (life expectancy < 6 months)

  • Patients who do not understand the Norwegian language.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Oslo Oslo Norway 0316
2 Oslo University Hospital Oslo Norway

Sponsors and Collaborators

  • University of Oslo
  • Oslo University Hospital
  • University of South-Eastern Norway

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christine Henriksen, Associate professor, University of Oslo
ClinicalTrials.gov Identifier:
NCT05997329
Other Study ID Numbers:
  • 569956
First Posted:
Aug 18, 2023
Last Update Posted:
Aug 23, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2023